Latham & Watkins represented the underwriters in the offering. Travere Therapeutics, Inc. executed its offering of US$275 million aggregate principal amount of 2.25% convertible senior notes due...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Bionomics in the offering. Bionomics Limited, a clinical-stage biopharmaceutical company, has announced the pricing of its initial public offering in the United States...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Alphatec Holdings in the transaction. Alphatec Holdings, Inc. (Nasdaq: ATEC) has announced the pricing of its offering of US$275,000,000 aggregate principal amount of...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented eFFECTOR in the transaction, eFFECTOR Therapeutics, Inc. (eFFECTOR), a biopharmaceutical company focused on pioneering the development of selective translation regulation inhibitors...
You must be a Standard 1 Year member to access this content.
